Condition: Macular Degeneration Choroidal Neovascularization · Sponsor: Hospital Authority, Hong Kong
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
This description comes directly from the study's public registry record.
Daniel Ho Tak Wong, FRCOphth (UK) · +852 3949 3411 · WHT454@ha.org.hk
Always discuss trial participation with your own doctor first.
| Department of Ophthalmology, United Chrisitian Hospital | Hong Kong, Hong Kong | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06742307